SCHEMBL7175183

SCHEMBL7175183

COc1cc(C)cc(OC)c1P(=O)(C(=O)c1ccccc1)C(=O)c1c(C)cccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.38
TRPM4 Q8TD43 1/20 0.37
MAPT P10636 3/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CXCL12 P48061 1/20 0.37
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
ATM Q13315 1/20 0.36
PDE4D Q08499 1/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177644 0.94 EPHX1 (0.40) EPHX1MAPTLMNAKDM4ECYP3A4
SCHEMBL7185414 0.92 NPC1 (0.39) EPHX1MAPTLMNAKDM4ECYP3A4
SCHEMBL7188198 0.92 EPHX1 (0.42) EPHX1MAPTLMNAKDM4ECYP3A4
SCHEMBL7175566 0.88 TRPM4 (0.41) TRPM4MAPTCYP3A4CXCL12NPC1
SCHEMBL7180674 0.86 CA12 (0.44) EPHX1MAPTLMNAKDM4ECYP3A4
SCHEMBL7177761 0.86 EPHX1 (0.43) EPHX1MAPTLMNAKDM4ECYP3A4
SCHEMBL7188630 0.85 TRPM4 (0.41) TRPM4MAPTCYP3A4NPC1RAB9A
SCHEMBL7189530 0.84 ALDH1A1 (0.40) TRPM4LMNAKDM4EHSD17B10NPC1
SCHEMBL7182401 0.84 MEN1 (0.40) KDM4ENPC1RAB9AATMPDE4D
SCHEMBL7182050 0.84 ATM (0.40) MAPTLMNAKDM4EHPGDTAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 EPHX1 4037/4885TRPM4 3654/4885MAPT 4870/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 EPHX1 4034/4885TRPM4 3840/4885MAPT 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.